Enovis (NYSE:ENOV) Trading 5.6% Higher – What’s Next?

Enovis Corporation (NYSE:ENOV)’s share price rose 5.6% during trading on Thursday . The company traded as high as $27.15 and last traded at $27.0330. 33,723 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 1,083,448 shares. The stock had previously closed at $25.59.

Analysts Set New Price Targets

ENOV has been the topic of a number of research analyst reports. Evercore set a $32.00 price target on Enovis in a report on Monday, July 6th. William Blair assumed coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating for the company. Wells Fargo & Company decreased their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. BMO Capital Markets assumed coverage on shares of Enovis in a research note on Wednesday, July 8th. They set an “outperform” rating and a $29.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $41.71.

Enovis Price Performance

The firm has a 50-day simple moving average of $23.49 and a 200-day simple moving average of $23.76. The firm has a market capitalization of $1.57 billion, a PE ratio of -1.37 and a beta of 1.39. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts forecast that Enovis Corporation will post 3.12 earnings per share for the current year.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have purchased 4,200 shares of company stock valued at $92,084 in the last 90 days. 2.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enovis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Arax Advisory Partners bought a new position in Enovis in the 4th quarter worth $29,000. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. GAMMA Investing LLC grew its holdings in Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after purchasing an additional 1,446 shares during the period. Danske Bank A S purchased a new stake in Enovis in the third quarter worth about $64,000. Finally, iSAM Funds UK Ltd purchased a new stake in Enovis in the third quarter worth about $80,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.